Court Approves $275 Million Price-Fixing Settlement

September 26, 2025

On September 26, 2025, the Honorable Cynthia M. Rufe granted final approval of the end-payer plaintiffs’ settlement with Sandoz Inc. and its subsidiaries. The settlement includes a monetary payment of between $230 million and $275 million.

The settlement resolves claims by FKB’s clients that Sandoz conspired with other generic pharmaceutical manufacturers to fix prices for certain generic drugs. These claims are part of the largest antitrust multidistrict litigation now pending in the country, in which plaintiffs allege that leading generic pharmaceutical manufacturers fixed prices for more than 180 drugs.

The case is In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2:16-MD-02724, in the U.S. District Court for the Eastern District of Pennsylvania.